AUG 20·SEC EDGARLow
Mackin James P sold $2.0M of AORT
Mackin James P (President & CEO) sold 70,000 shares of ARTIVION, INC. (AORT) at $28.96 ($2.03M total) on 2026-08-19.
StockNYSE · US · USDHealthcare · Medical Devices
$AORT
ARTIVION, INC.
alphai earnings readsecond quarter of 2026 · AUG 6Artivion Reports Second Quarter 2026 Financial ResultsVerdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $AORTvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $AORT in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $2.1M 4 txs
GREEN ANDREW M1× · $18K
10b5-1 share of filings0%
Top stories · $AORTMore →
AUG 19·simplywall.st
Does Revenue Growth Amid New Losses Reshape The Bull Case For Artivion (AORT)?
Artivion (AORT) reported Q2 2026 revenue of $125.76M, up from $112.97M a year earlier, but shifted from net income to a loss of $13.51M. H1 2026 revenue rose to $242.09M, but the company moved to a net loss of $12.09M. The company projects $619.8M revenue and $44.7M earnings by 2029, requiring 10.6% yearly revenue growth.
AUG 19·financialcontent.com
Why Artivion (AORT) Stock Is Trading Up Today
Artivion (AORT) shares rose 2.5% after Canaccord Genuity raised its price target to $40, citing strong Q2 revenue of $125.8M. The stock later cooled to $29.57, up 2.3%. The company's shares have been volatile, with a 26.8% drop in May after missing earnings estimates and lowering guidance. AORT is down 33.5% YTD.
AORT sentiment & insider activity
Recent AORT coverage spans earnings, financial news and insider activity.
In the last 30 days, AORT insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($2.1M). The most active reporter was GREEN ANDREW M, SVP, Regulatory and Quality, with 1 filing.
What's driving AORT
Insider sale by the CEO may signal reduced confidence, potentially pressuring the stock lower.
Earnings miss may pressure the stock short-term; however, FDA approval for AMDS could support upside if margins improve.
Analyst upgrade lifts sentiment and short‑term buying pressure.
Near-term focus is on AMDS US commercialization ramp and Endospan integration, offset by margin pressure from R&D and Austin production ramp costs.
Positive product and pipeline narrative (AMDS adoption, NEXUS ramp, On-X share gains) but with margin pressure from R&D and integration.
alphai scores every news story that mentions AORT with an AI model for sentiment and relevance, and aggregates insider trades from ARTIVION, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $AORT
Score
Mackin James P sold $2.0M of AORT
Mackin James P (President & CEO) sold 70,000 shares of ARTIVION, INC. (AORT) at $28.96 ($2.03M total) on 2026-08-19.
1 min readDoes Revenue Growth Amid New Losses Reshape The Bull Case For Artivion (AORT)?
Artivion (AORT) reported Q2 2026 revenue of $125.76M, up from $112.97M a year earlier, but shifted from net income to a loss of $13.51M. H1 2026 revenue rose to $242.09M, but the company moved to a net loss of $12.09M. The company projects $619.8M revenue and $44.7M earnings by 2029, requiring 10.6% yearly revenue growth.
3 min read
Why Artivion (AORT) Stock Is Trading Up Today
Artivion (AORT) shares rose 2.5% after Canaccord Genuity raised its price target to $40, citing strong Q2 revenue of $125.8M. The stock later cooled to $29.57, up 2.3%. The company's shares have been volatile, with a 26.8% drop in May after missing earnings estimates and lowering guidance. AORT is down 33.5% YTD.
2 min read
Artivion (AORT) Q2 2026 Earnings Call Transcript
Artivion (AORT) reported Q2 2026 revenue of $125.8M, up 9% constant currency, and adjusted EBITDA of $26.4M. The company completed the Endospan acquisition and received late-June FDA PMA approval for AMDS, expecting faster account conversion. Full-year guidance was reiterated at $480M to $496M revenue and $92M to $99M adjusted EBITDA; FCF was negative $12M.
7 min readAORT Q2 Deep Dive: Product Momentum and Pipeline Expansion Support Positive Outlook
Artivion’s Q2 update highlights 12% YoY growth in stent graft revenues and 18% growth in its On-X mechanical heart valve portfolio. The company says its NEXUS Aortic Arch Stent Graft acquisition (Endospan) completed and that AMDS received full FDA approval, supporting adoption. Management expects near-term margin and cash flow pressure from R&D and integration.
6 min readArtivion: Q2 Earnings Snapshot
Artivion, Inc. (AORT) reported Q2 revenue of $125.8 million and a net loss of $13.5 million, or 28 cents per share, versus a profit a year earlier. Adjusted earnings were 13 cents per share. The company expects full-year revenue of $480 million to $496 million. Shares fell sharply year to date.
3 min read
Artivion (NYSE:AORT) Delivers Strong Q2 CY2026 Numbers
Artivion (NYSE:AORT) reported Q2 CY2026 revenue of $125.8 million, up 11.3% year over year and 4.4% above Wall Street estimates, according to the company. Non-GAAP EPS was $0.13, clearing consensus. The company guided full-year revenue to about $488 million and expects EPS around $0.54.
4 min readARTIVION, INC. (AORT): Results of Operations and Financial Condition
ARTIVION, INC. (AORT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Phone: 332-895-3222 Chief Operating Officer & investors@artivion.com Chief Financial Officer Phone: 770-419-3355 Artivion Reports Second Quarter 2026
7 min read
Artivion (AORT) To Report Earnings Tomorrow: Here Is What To Expect
Artivion (NYSE: AORT) will report earnings Thursday after the bell. Last quarter it posted revenue of $116.3M, up 17.5% YoY, but missed analysts’ EPS and slightly missed full-year revenue guidance. This quarter consensus calls for 6.7% YoY revenue growth. Analysts’ estimates were largely unchanged; average price target is $42 vs $27.30.
3 min readBelow Expected Sales for AMDS Hurt Artivion (AORT) in Q2
In its Q2 2026 investor letter, Alger Weatherbie Specialized Growth Fund cited Artivion, Inc. (NYSE:AORT) after the company reported in-line Q1 results but modestly lowered its full-year outlook. The update attributed the change to slower-than-expected starter set sales for AMDS. AORT closed July 20, 2026 at $25.37, with a $1.23B market cap.
4 min read